UNSPSC 51283002: Clindamycin

This classification denotes a lincosamide antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3U02EL437C. European Medicines Agency schedules Clindamycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06665MIG. Clindamycin generally arises in the molecular formula C18H33CLN2O5S.

UNSPSC 51283002 Clindamycin is a Commodity code that in practice encompasses a broader range of pharmaceutical and medical supply procurement by state and local government bodies than the code name alone suggests. Recent state and local opportunities tagged under this code show solicitations for naloxone and drug deactivation systems, medical and first aid supplies for emergency response, and participation in multi-state cooperative purchasing agreements for generic pharmaceuticals and over-the-counter products. The issuing bodies include county health departments (Seminole County, Florida), city fire departments (City of Tampa), state health agencies (Texas Health and Human Services Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities across multiple states including Oregon). Scope varies from direct procurement of specific medical supplies to information-gathering on direct-to-manufacturer prescription program models and enrollment in cooperative purchasing vehicles where vendors supply products through authorized wholesalers.

Recent activity spans Florida, Texas, Minnesota, and Oregon. The City of Tampa issued an IFB on March 25, 2026 (due March 13, 2026) for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division, with an estimated contract amount of $700,000 and a 5 percent bid discount sheltered for certified Small Local Business Enterprises. Seminole County, Florida solicited 1,900 units of naloxone and 800 Safe Drug Deactivation Systems annually through IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) with quarterly deliveries. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP for generic multi-source pharmaceuticals and OTC products (due March 26, 2026, questions cutoff February 18, 2026) requiring vendors to supply through three authorized wholesalers with contract effectiveness July 1, 2026. The Texas Health and Human Services Commission issued an RFI (posted April 3, 2026) to gather market intelligence on direct-to-manufacturer prescription programs without formal competitive timelines or award values, positioning it as exploratory procurement preceding formal RFP issuance.